Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A, Tatochenko V, Briko N. Marijam A, et al. Among authors: scherbakov m. Hum Vaccin Immunother. 2022 Nov 30;18(5):2045152. doi: 10.1080/21645515.2022.2045152. Epub 2022 Mar 8. Hum Vaccin Immunother. 2022. PMID: 35258445 Free PMC article.
A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.
Namazova-Baranova L, Habib MA, Povey M, Efendieva K, Fedorova O, Fedoseenko M, Ivleva T, Kovshirina Y, Levina J, Lyamin A, Ogorodova L, Reshetko O, Romanenko V, Ryzhenkova I, Sidorenko I, Yakovlev Y, Zhestkov A, Tatochenko V, Scherbakov M, Shpeer EL, Casabona G; OKAH-182 Russia Study Group. Namazova-Baranova L, et al. Among authors: scherbakov m. Hum Vaccin Immunother. 2022 Jan 31;18(1):1959148. doi: 10.1080/21645515.2021.1959148. Epub 2021 Aug 26. Hum Vaccin Immunother. 2022. PMID: 34435933 Free PMC article. Clinical Trial.
Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study.
Asatryan A, Meyer N, Scherbakov M, Romanenko V, Osipova I, Galustyan A, Shamsheva O, Latysheva T, Myasnikova T, Baudson N, Dodet M, Xavier S, Harrington L, Kuznetsova A, Campora L, Van den Steen P. Asatryan A, et al. Among authors: scherbakov m. Hum Vaccin Immunother. 2021 Mar 4;17(3):723-730. doi: 10.1080/21645515.2020.1796423. Epub 2020 Aug 26. Hum Vaccin Immunother. 2021. PMID: 32845735 Free PMC article. Clinical Trial.
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.
Romanenko V, Osipova I, Galustyan A, Scherbakov M, Baudson N, Farhi D, Anaya L, Kuriyakose SO, Meyer N, Janssens W. Romanenko V, et al. Among authors: scherbakov m. Hum Vaccin Immunother. 2020 Sep 1;16(9):2265-2273. doi: 10.1080/21645515.2020.1720437. Epub 2020 Feb 12. Hum Vaccin Immunother. 2020. PMID: 32048889 Free PMC article. Clinical Trial.
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group. Tjalma WA, et al. Int J Cancer. 2013 Feb 15;132(4):854-67. doi: 10.1002/ijc.27713. Epub 2012 Jul 24. Int J Cancer. 2013. PMID: 22752992 Free article.